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PURPOSE. The purpose of this study was to determine the safety of topical ocular
administration of a cross-linked, modified hyaluronic acid (xCMHA-S) hydrogel, and its
effectiveness in accelerating repair and closure of acute and nonhealing corneal ulcers in
companion animals as a veterinary treatment and its utility as a model for therapy in human
corneal ulceration.
METHODS. Two concentrations of xCMHA-S (0.33% and 0.75%) were topically administered to
the eyes of rabbits six times daily for 28 days to assess safety. Then, 30 dogs and 30 cats with
spontaneous acute corneal ulcers were treated with either xCMHA-S (0.75%) or a non–cross-
linked hyaluronic acid (HA) solution (n ¼ 15 per group for each species), three times daily
until the ulcer had healed. Finally, 25 dogs with persistent nonhealing corneal ulcers were
treated with xCMHA-S (0.75%) twice daily until the ulcer had healed.
RESULTS. Both concentrations of the xCMHA-S hydrogel were well tolerated, safe, and
nontoxic in the 28-day exaggerated dosing study in healthy rabbits. Topically applied xCMHA-
S significantly accelerated closure of acute corneal stromal ulcers in dogs and cats compared
with a non–cross-linked HA solution. Further, topical administration of the xCMHA-S aided in
closure of nonhealing corneal stromal ulcers in dogs.
CONCLUSIONS. Hyaluronic acid has previously been shown to aid in corneal wound repair. This
study demonstrates that a cross-linked, modified HA hydrogel provides further benefit by
accelerating time to corneal wound closure compared to a non–cross-linked HA solution in
companion animals, and therefore may be beneficial in fulfilling an unmet need in humans.
Keywords: corneal repair, crosslinked hydrogel, modified hyaluronic acid, non-healing ulcer
Corneal epithelial and stromal defects with ulceration arecommon ocular conditions both in humans and in
companion animal species, such as dogs and cats. In humans,
eye injuries represent up to 18% of emergency room traumas,
corneal abrasions account for up to 4% of all US occupational
injuries, and approximately 20% of patients with facial burns
have ocular injury.1 Post-traumatic abrasions are a common
problem in humans in both developed2 and Third World
countries.3,4 According to the World Health Organization, it is
estimated that corneal opacities, including corneal ulceration,
are the fourth leading cause of blindness worldwide.5 The same
is true in canine and feline patients where many corneal
ulcerations have a traumatic origin and can lead to corneal
blindness.6 In humans and animals, superficial corneal lesions
can heal rapidly and without complication, but stromal ulcers
often fail to follow such a benign self-healing course and can
become a sight threatening emergency with corneal scarring,
ulceration, thinning, and even perforation if not treated
promptly. Therefore, a topical treatment that aids in the
management and accelerated closure of corneal wounds would
help reduce the risk of infections and scarring, and thus
improve visual outcomes in all species.
Hyaluronic acid (HA), a high molecular weight glycosami-
noglycan, is recognized as having ameliorative effects that can
help heal epithelial defects throughout the body, and has been
shown to enhance and aid in corneal healing.7–9 Hyaluronic
acid is widely used as a topical ocular tear replacement therapy
and is the standard of care for dry eye in Europe and Asia.10
These HA-containing solutions provide transient, symptomatic
relief and have excellent safety profiles. The main limitation
with many of these solutions is the rapid clearance of the HA
from the eye, requiring that drops be administered at least four
times a day and often more frequently. Although HA solutions
have been shown to have a longer residence time over other
dry eye lubricants, the half-life of the HA on-eye was still on the
order of minutes.11 A subsequent study with fluorescently-
tagged HA showed 90% clearance of an HA solution from the
surface within 30 minutes.12 Thus, an HA-based formulation
that has increased ocular residence time could lead to
decreased dosing frequency, while still having the beneficial
properties of the HA, ultimately aiding in the accelerated
closure of corneal and ocular surface defects. A cross-linked
thiolated carboxymethylated HA (xCMHA-S) hydrogel has
previously been shown to be beneficial in managing the
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symptoms associated with keratoconjunctivitis sicca in
dogs.13,14
Given the safety and efficacy in treating dry eye in animals,
the current study builds on a previous report demonstrating
the beneficial effects of xCMHA-S in corneal wound models in
rabbits.15 In the current study, the safety profile of topical
ocular administration of xCMHA-S with exaggerated dosing in
rabbits was first demonstrated followed by an efficacy study
comparing the time to wound closure of spontaneously
occurring corneal stromal ulcers in dogs and cats in a clinical
setting using xCMHA-S versus a non–cross-linked HA solution.
Finally, the effectiveness of xCMHA-S to aid in the closure of




CMHA-S was synthesized and analyzed as previously de-
scribed.13,15 A solution of CMHA-S (0.33% or 0.75% wt/vol)
in PBS (pH 7.4) was then filter-sterilized, cross-linked to form a
hydrogel (xCMHA-S), and packaged aseptically into sterile 3-mL
eye drop bottles as previously described.13 The xCMHA-S
hydrogels are commercially available under the Remend label
(Bayer Animal Health, Shawnee, KS, USA).
Safety and Toxicity in Rabbits
Thirty healthy New Zealand White rabbits (15 female, 15 male)
were assigned to one of three groups: Group 1 (6 female, 6
male) to receive 0.33% xCMHA-S; Group 2 (6 female, 6 male) to
receive 0.75% xCMHA-S; Group 3 (3 female, 3 male) to receive
PBS (control). One drop of xCMHA-S (0.33% or 0.75%) or PBS
alone was administered six times a day (an exaggerated dosing
regimen) via topical application to both eyes of the rabbits for
28 days. Each dose (40 lL) was pipetted with a calibrated
pipette and sterile tip for each eye; to minimize runoff, each
eye was gently closed for a few seconds after dosing. Blood and
urine were collected prior to dosing and prior to necropsy for
complete blood count, clinical chemistry, coagulation factor
testing, and urinalysis. Gross ocular observations, which
consisted of a visual appraisal for swelling, discharge, and/or
irritation of the eye, were performed daily. Clinical ophthalmic
examinations, using slit-lamp biomicroscopy and indirect
ophthalmoscopy, were performed weekly for the study
duration. Examinations used a modified McDonald-Shadduck
scoring system, and were performed by board-certified
veterinary ophthalmologists (R Merideth, E Moeller, Eye Care
for Animals, San Diego, CA, USA). Intraocular pressure (IOP)
measurements were taken prior to dosing and prior to
euthanasia for all animals (Reichert Model 30 pneumotonom-
eter, Depew, NY, USA). One male and one female from Group
3, and two males and two females from both Groups 1 and 2,
were observed for an additional 14 days after the final dose was
administered.
Following euthanasia, the globes and adnexa were collect-
ed, preserved in 10% formalin, and processed for histopathol-
ogy. The tissues were embedded in paraffin, sectioned, and
stained with hematoxylin and eosin. The sections were
examined under light microscopy, and specific areas that were
evaluated included: conjunctiva, cornea, anterior chamber, iris,
retina, lenses, choroid, vitreous, clear, and ocular adnexal
tissue. For nonneoplastic findings, severity was graded on a
five-point scale, where 1¼minimal, 2¼mild, 3¼moderate, 4¼
marked, and 5¼ severe. Corneal thickness was measured from
the surface of the epithelium to the posterior surface of the
endothelium in the central cornea of each eye in a masked
manner. Three measurements were taken in the central and
paracentral cornea using a micrometer eyepiece on the
microscope. These measures were directly perpendicular to
the surface of the cornea.
This study was approved by the Institutional Animal Care
and Use Committee at Absorption Systems (San Diego, CA,
USA) and conducted in accordance with the Good Laboratory
Practice for Nonclinical Laboratory Studies (Code of Federal
Regulations US FDA 21 CFR Part 58) and Authorized Service
Interruption Standard Operating Procedures. All animals were
treated according to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research.
Acute Ulcer Healing in Dogs and Cats
Thirty dogs and 30 cats kept as companion animals in home
environments and diagnosed with acute corneal stromal
ulceration by the managing veterinary ophthalmologist
(DLW) were included in the study. The animals were subject
to a full systemic and ophthalmic examination using direct and
indirect ophthalmoscopy and slit-lamp biomicroscopy, and
those with concurrent ocular or systemic disease were
excluded from the study. Ulcer depth was assessed using the
slit-lamp biomicroscope and classified as superficial, mid, or
deep stromal ulceration. Corneal vascularization and haze were
assessed based on the following scale: 0¼ none, 1¼mild, 2¼
moderate, 3 ¼ severe. Intraocular pressure was measured as
previously described. The animals were randomly assigned to
receive xCMHA-S (0.75%) or a commercially available non–
cross-linked HA solution (0.3%; iDrop Vet Plus; I-MED Animal
Health, Dollard-des-Ormeaux, Quebec, Canada) applied topi-
cally three times daily, with topical antibiotic, 0.5% chloram-
phenicol drop, applied concurrently at home by their owners.
The investigator was masked as to which group each animal
was assigned. Animals were examined clinically by direct and
indirect ophthalmoscopy and by slit-lamp biomicroscopy
weekly until the ulcer had closed, as demonstrated by failure
of the corneal surface to stain with fluorescein dye.
Treatment of Nonhealing Ulcers in Dogs
Dogs with persistent nonhealing corneal epithelial defects and
stromal ulceration, that is to say ulceration that had not healed
within approximately 2 weeks despite standard antibiotic and
tear replacement therapy, were referred to a veterinary
ophthalmologist (DLW) and enrolled in this study. Dogs were
included if they were not suitable candidates for surgery either
because of age, anesthetic risk, or for financial reasons.
Informed consent was provided by the owners for their pets
to be included in this study. All dogs underwent full clinical
and ophthalmic examination using direct and indirect ophthal-
moscopy and slit-lamp biomicroscopy. Tear production was
measured using the Schirmer tear test and IOP was measured
by tonometry using a rebound tonometer (Tonovet; I-Care,
Vantaa, Finland). Epithelial size and ulcer width was assessed
using a single drop of fluorescein dye (Minims; Chauvan
Pharmaceuticals, Watford, UK) flushed away with sterile saline.
Ulcer depth was assessed using the slit-lamp biomicroscope
and classified as (1) superficial epithelial erosion, (2) superficial
stromal ulceration, (3) midstromal ulceration, or (4) deep-
stromal ulceration. Animals with descemetoceles or those
considered at imminent risk of corneal rupture were excluded
from the study and treated surgically. Animals with excessive
ocular pain were excluded from the study and treated
accordingly medically with systemic and topical pain relief.
Twenty-five dogs referred by first opinion veterinarians with
nonhealing corneal ulcers were subsequently treated with
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xCMHA-S (0.75%). Dogs appropriate to be included in this
study must have had epithelial erosions or stromal ulceration
with failure to heal at approximately 2 weeks, and thus
considered as chronic lesions unlikely to heal spontaneously.
After ophthalmic examination and inclusion in the study,
previous treatments were stopped, and animals were topically
administered the xCMHA-S twice daily with examinations,
thenceforth conducted weekly. Time to corneal ulcer healing
on xCMHA-S was noted, as determined by failure of the ocular
surface to stain with fluorescein dye.
Both studies were reviewed and accepted by the Ethics and
Welfare Committee of the Department of Veterinary Medicine,
University of Cambridge, Cambridge, United Kingdom, and all
animals were treated in accordance with the welfare guidelines
in the Royal College of Veterinary Surgeons Guide to
Professional Conduct. The owners provided informed consent.
Statistical Analysis
For the acute ulcer healing study, comparisons between the
two groups for each species were determined using an
unpaired Student’s t-test; comparison between corneal haze
pre- and posttreatment within a group was determined using a
paired Student’s t-test. The number of dogs and cats included
in the study was determined by a power analysis.16 Using a
desired effect size (the difference in mean time to healing
between the treatment groups) of 5 days, a type I error of 0.05,
a power of 0.8, and an SD between 4 and 5 days, a sample size
needed for each treatment group was between 11 and 16. For
the nonhealing chronic ulcer study, time to wound closure
with xCMHA-S was compared with the time without healing
prior to use of xCMHA-S using a v2 23 2 contingency table.
RESULTS
Safety and Toxicity in Rabbits
The safety of the xCMHA-S gel was determined using 63 daily
topical administration to the eyes of healthy rabbits over 28
days. The xCMHA-S was very well tolerated at both concen-
trations with only intermittent mild þ1 grade conjunctival
congestion and mild clinically insignificant swelling of the third
eye lid observed in four animals in Group 1, two in Group 2,
and three in Group 3 over the course of the study. Following
euthanasia, evaluation of the globes and adnexa histopatho-
logically showed no sign of any untoward inflammation or
toxicity in any of the eyes in all groups and time points, and
there was no significant difference in corneal thickness
between the PBS and xCMHA-S groups, indicating the safety
of the xCMHA-S gel over at least 28 days.
Acute Ulcer Healing in Dogs and Cats
The utility of the xCMHA-S gel in accelerating closure of acute
corneal ulcers was determined in companion animals kept in
home environments. One cat was lost to follow-up, leaving 15
cats in the xCMHA-S group and 14 in the non–cross-linked HA
group. For dogs, there were 15 animals in each of the xCMHA-S
and non–cross-linked HA groups. The breed, age, sex, depth
and area of ulcer, degree of corneal vascularization, IOP, and
corneal haze pre- and posttreatment for each dog and cat is
shown in Tables 1 and 2, respectively. There was no significant
difference in age between the two groups for each species.
Similarly, although not matched for ulcer severity due to
randomization in assignment to groups, the treatment groups
were not significantly different in their ulcer depth or area, as
shown in Tables 1 and 2. Further, there was no significant
difference in corneal vascularization, IOP, or corneal haze
between the two groups in each species. As shown in Figure 1,
canine corneal ulcers receiving xCMHA-S closed significantly
faster (14.8 6 4.1 days) than those receiving the non–cross-
linked HA (18.3 6 4.9 days; P ¼ 0.04). Likewise, feline ulcers
receiving xCMHA-S closed significantly faster (21.0 6 11.0
days) than those receiving the non–cross-linked HA (31.8 6
10.3 days; P¼ 0.01). Although there was no significant change
in corneal haze from pre- to posttreatment for either group of
the dogs, there was a significant decrease in haze from pre- to
posttreatment for both groups of the cats (P ¼ 0.003 for the
non–cross-linked HA group, P¼0.007 for the xCMHA-S group).
Treatment of Chronic Nonhealing Ulcers in Dogs
The ability of xCMHA-S gel to aid closure of chronic nonhealing
ulcers was also examined in dogs kept as companion animals in
home environments. Results of time to ulcer healing following
treatment with xCMHA-S for dogs in this study are shown in
Table 3 together with the type of ulcer involved and the time
without healing before referral. Where ulcer healing occurred,
the resulting stroma was generally opaque (Fig. 2), the
epithelium was intact, and the dogs were pain free (as
reported by their owners). The average duration of the ulcer
before use of xCMHA-S was 25.5 6 8.3 days while the mean
time to ulcer healing when treated with xCMHA-S was 13.4 6
4.2 days, these times being significantly different (P ¼
0.00005). Dogs with recurrent epithelial erosion associated
with defective basal epithelial cell adhesion to the underlying
basement membrane (termed spontaneous chronic corneal
epithelial defects [SCCEDs])17,18 and analogous to recurrent
epithelial erosions in humans19,20) did not heal with xCMHA-S
and required epithelial debridement before healing occurred.
These ulcers are readily diagnosed as they have a clearly
defined devitalized epithelial margin17,18 and are denoted in
Table 3 as those with superficial erosions. One pug with a deep
stromal ulcer experienced corneal rupture through self-trauma.
These animals were all subsequently removed from the study
and treated accordingly. Where chronic nonhealing ulcers did
heal, time to healing once placed on the xCMHA-S was similar
to that for acute ulcers.
DISCUSSION
Ocular injuries are prevalent in both humans and companion
animals, and delayed corneal epithelial healing can lead to
subsequent corneal infections with further complications,
such as corneal scarring, thinning, ulceration, and even
perforation. Therefore, a product that can aid in the healing
process and reduce time to corneal epithelial healing would be
beneficial in all species.
Solutions of non–cross-linked HA, at 1.5 to 10 mg/mL, have
previously been shown to enhance corneal wound healing in
debridement or abrasion studies in rats, rabbits, and humans.7–
9 Although a study recently reported that a solution of non–
cross-linked HA at 2 mg/mL had no effect on wound closure,
compared with controls, in a corneal debridement model in
dogs, the study was limited to only three animals per group.21
It remains unclear exactly what mechanism is responsible for
enhanced corneal wound repair, as in vitro and/or ex vivo
reports have indicated either an increase in corneal epithelial
cell proliferation22 or cell migration.23 The differences in these
studies, however, may be due to timing, as the first study
examined the effect of HA on cells at 15 hours and the second
examined the effect at 12 and 16 days. Regardless of the
mechanism, HA does appear to provide a benefit to the corneal
wound repair process following debridement.
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Although the non–cross-linked HA solution used in the rat
debridement model enhanced wound healing, it did not
provide the same acceleration of healing in an alkali burn
model in rats7. However, a cross-linked HA gel, similar to the
hydrogel used in the current study, was shown to accelerate
corneal wound healing in both a debridement and a burn
model in rabbits.15 Thus, with the deeper wound created by
the alkali burn, a cross-linked HA may provide more benefit,
potentially due to a longer residence time on the ocular
surface. Despite the successful use of both non–cross-linked
and cross-linked HA in aiding corneal wound repair in wound
models, the current study appears to be first one to report the
use of cross-linked HA in companion animals with spontaneous
corneal ulcers.
Here, in dogs and cats kept as companion animals in home
environments, we have shown that a cross-linked gel
formulation, xCMHA-S, based on a modified HA, was able to
accelerate time to epithelial closure both in acute and chronic
corneal stromal defects. The xCMHA-S hydrogel was shown to
be well tolerated, safe, and nontoxic in a GLP 28-day rabbit
study. Subsequently, topical administration of the xCMHA-S led
to significantly faster closure of acute corneal stromal ulcers in
TABLE 1. Information on Dogs With Corneal Stromal Ulcers Treated With Cross-Linked CMHA-S Hydrogel (xCMHA-S) or Non–Cross-Linked HA
Solution


















901 JRT 6 Fn Mid 1 12 6.5 18 2 3
904 Shih Tzu 7 Fn Mid 2 10 7 7 3 2
905 X-bred 9 Fn Superficial 1 14 5 15 2 1
909 Golden Ret 10 Mn Mid 1 13 7 20 3 2
910 CKCS 8 Mn Mid 2 10 5 22 3 2
913 Lhasa Apso 4 Me Mid 1 12 6.5 18 3 3
914 WHWT 3 Fe Superficial 0 16 7 12 1 1
919 Lhasa Apso 8 Mn Mid 1 13 7 14 2 3
920 Dandie Din 6 Mn Superficial 0 15 7.5 19 1 2
922 GSD 8 Me Mid 1 11 6.5 18 3 2
923 X-bred 8 Fn Mid 2 10 7 22 3 3
924 Yorkshire T 6 Fn Mid 1 13 6.5 26 2 2
925 Border T 8 Me Mid 1 12 7 20 3 2
929 X-bred 9 Me Mid 0 15 7.5 25 2 1
930 St. Bernard 6 Fe Superficial 1 14 6.5 18 1 1
Mean 6 SD 7.1 6 1.9 1.0 6 0.7 12.7 6 1.9 6.6 6 0.7 18.3 6 4.9 2.3 6 0.8 2.0 6 0.8
xCMHA-S
902 X-bred 7 Mn Mid 1 12 7 14 2 1
903 Lab 5 Mn Mid 1 14 8 18 2 2
906 CKCS 7 Fn Superficial 0 17 7.5 23 1 1
907 WHWT 8 Fn Mid 2 12 8 22 3 2
908 X-bred 9 Fn Mid 2 10 6.5 14 3 2
911 X-bred 7 Me Mid 1 14 7 17 3 3
912 Boston T 8 Fn Superficial 0 16 6 9 2 1
915 Lab 6 Fn Superficial 0 17 7 14 1 1
916 Dalmatian 7 Fe Mid 1 12 6 10 2 2
917 Briard 8 Fn Superficial 1 13 7 17 1 1
918 Golden Ret 6 Fn Mid 2 10 6.5 15 2 1
921 X-bred 7 Mn Superficial 1 12 7 12 1 1
926 Lhasa apso 6 Fe Superficial 0 14 7 10 1 2
927 Lakeland T 9 Mn Superficial 1 13 7.5 13 2 2
928 Lab 10 Fn Mid 1 10 7 14 3 2
Mean 6 SD 7.3 6 1.3 0.9 6 0.7 13.1 6 2.3 7.0 6 0.6 14.8 6 4.1 1.9 6 0.8 1.6 6 0.6
JRT, Jack Russell terrier; Ret, retriever; CKCS, Cavalier King Charles spaniel; WHWT, West Highland white terrier; Din, dinmont; GSD, German
Shepherd dog; T, terrier; Lab, Labrador retriever; Fn, neutered female; Fe, unaltered female; Mn, neutered male; Me, unaltered male; tx, treatment; 0,
none; 1,mild, 2, moderate; 3, severe.
FIGURE 1. Corneal ulcer healing time in cats and dogs. Bars represent
95% confidence intervals of the means; lines represent range of values
obtained. *P¼ 0.01; **P¼ 0.04.
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TABLE 2. Information on Cats with Corneal Stromal Ulcers Treated With xCMHA-S or Non–Cross-Linked HA Solution


















801 Dsh 8.2 Mn Mid 0 14 6 13 2 1
805 Dsh 8.2 Mn Mid 0 16 7 22 2 2
806 Dsh 8.7 Mn Mid 1 12 7.5 27 2 1
807 Dsh 10.1 Mn Mid 1 13 7 28 2 2
810 Dsh 13.1 Fn Mid 0 16 6.5 28 1 1
813 Dsh 4.7 Fe Mid 1 18 7 29 2 1
814 Mau 12.0 Fn Mid 1 15 7 29 3 2
817 Dsh 10.1 Mn Mid 2 16 7.5 30 3 3
820 Dsh 7.8 Fn Mid 1 14 8 31 2 2
823 Dsh 6.2 Fn Mid 0 12 7 33 2 2
824 Dsh 8.2 Fn Mid 0 14 7.5 34 3 2
825 Sia 9.2 Fn Mid 1 17 4 37 2 1
827 Bur 8.2 Fn Deep 2 12 8.5 51 3 3
830 Dsh 5.0 Fe Mid 0 15 7 53 3 2
Mean 6 SD 8.6 6 2.4 0.7 6 0.7 14.6 6 1.9 6.9 6 1.0 30.6 6 10.9 2.3 6 0.6 1.8 6 0.7
xCMHA-S
803 Dsh 7.5 Mn Mid 1 14 6.5 7 3 2
804 Per 10.3 Mn Mid 1 16 7 10 3 2
808 Dsh 3.4 Mn Superficial 0 15 5.5 12 1 2
809 Dlh 8.2 Mn Mid 0 15 7 12 2 1
811 Dsh 14.9 Fn Deep 2 12 7 14 2 1
812 Dsh 10.8 Fn Mid 1 14 7 14 2 2
815 Dsh 8.2 Mn Mid 0 16 7.5 16 3 1
816 Dsh 14.2 Fn Mid 0 17 6.5 17 2 1
818 Dsh 4.7 Me Deep 1 13 7 19 2 2
819 Dsh 6.3 Fn Deep 2 11 7 27 3 2
821 Brsh 6.5 Me Superficial 0 15 7.5 27 1 1
822 Dsh 7.1 Fn Mid 1 14 7 28 2 1
826 Dsh 14.5 Fn Deep 2 13 7 29 3 2
828 Dsh 9.8 Mn Mid 1 17 8 37 2 2
829 Dsh 13.5 Fn Superficial 0 19 8.5 46 1 1
Mean 6 SD 9.3 6 3.7 0.8 6 0.8 14.7 6 2.1 7.1 6 0.7 21.0 6 10.9 2.1 6 0.7 1.5 6 0.5
Brsh, British shorthair; Bur, Burmese; Dsh, domestic shorthair; Dlh, domestic longhair; Per, Persian; Sia, Siamese; tx, treatment.
FIGURE 2. Healing of a corneal ulcer on a 7-year-old mixed-breed dog. The dog is case #4 in Table 3. (A) Day 21 of the nonhealing ulcer; (B) the
healed ulcer after 14 days of treatment with xCMHA-S.
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dogs and cats compared with a non–cross-linked HA solution.
Further, topical administration of the xCMHA-S aided in closure
of nonhealing corneal stromal ulcers in dogs. The product did
not improve healing in animals with chronic nonhealing
superficial erosions where defective epithelial cell adhesion
to the underlying basement membrane (recurrent erosions, or
SCCEDs) was present and where epithelial debridement was
required prior to healing.
While the portion of our study that examined the effect of
the xCMHA-S on acute corneal wound healing in cats and dogs
was masked and randomized, the portion using the xCMHA-S
for nonhealing ulcers was not. Although it could be argued that
simply removing the animals from their previous tear
replacement would lead to the ultimate wound closure, and
not the use of the xCMHA-S, we were reluctant to potentially
extend the period of nonhealing by first removing them from
the tear replacement for a period of time, and then beginning
use of the xCMHA-S. Further, as there was no appropriate
alternative to use for treating the nonhealing ulcers in a
manner that could be masked, the study could not be masked
or randomized. This aspect of removing the animals from their
previous treatment regimen also has the potential that the
ulcers, from the point of removal of the other treatment, could
then be considered ‘‘acute’’ ulcers, and may account for the
similar healing times for dogs administered xCMHA-S in the
two portions of the study.
The average healing time for acute corneal ulcers was
slower in cats than dogs in this study, which was unexpected.
Although there have been previously reported studies on
healing of experimentally induced corneal ulcers in dogs,21,24
there have been no equivalent studies published on corneal
ulcer healing in cats, nor any studies directly comparing the
two species. The feline ulcers in this study were slightly larger
in width and on average more severe in depth than the canine
lesions, and thus could have resulted in some difference in
healing time. However, in both cats and dogs, some more
severe stromal ulcers (in terms of depth) healed faster than
more superficial lesions. This may be due to the fact that these
are clinical cases, companion animals living in homes rather
than laboratory animals in more controlled experimental
environments. As such, variations in temperature and humidity,
degree of self-trauma, presence of other animals or aspects of
the home environment that may affect the eye, and owner
compliance are all confounding variables that have the
potential to influence healing rates.
It should be stressed that complicated cases of nonhealing
ulcers, such as those having a devitalized nonadherent epithe-
lium or having a concurrent condition, should be treated
accordingly and may require surgical intervention both in
humans and in animals. Nevertheless, with the benefits shown
for accelerating corneal epithelial and stromal ulcer closure in
companion animals, this xCMHA-S gel formulation also is likely to
be useful in aiding corneal epithelial defect closure in humans.
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15 Boxer 8 Fn Superficial stromal 24 4 14
16 Pug 2 Me Deep stromal 24 3 14
17 JRT 8 Fn Superficial stromal 24 6 14
18 X-bred 13 Me Deep stromal 21 3 Nh (required cpg)
19 Boxer 8 Me Superficial erosion 42 7 Nh (required edgk)
20 St Bernard 4 Fe Superficial stromal with entropion 14 8 Nh (required correction of entropion)
21 Corgi 12 Fe Superficial erosion 32 5 Nh (required edgk)
22 Pug 3 Me Deep stromal 12 2 Nh (ruptured)
23 Boxer 8 Fn Superficial erosion 14 5 Nh (required edgk)
24 ECS 9 Mn Superficial erosion 21 4 Nh (required edgk)
25 Corgi 12 Fe Superficial erosion 32 4 NH (required EDGK)
Mean 6 SD 25.5 6 8.3 4.5 6 1.5 13.4 6 4.2
ECS, English cocker spaniel; NH, not healed on xCMHA-S; CPG, conjunctival pedicle graft; EDGK, epithelial debridement and grid keratotomy.
Days unhealed indicates the number of days the animal had the ulcer and was treated with SOC prior to referral and beginning treatment with
xCMHA-S.
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